1
|
Tripathi R, Kumar P. Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases. Integr Biol (Camb) 2023; 15:zyad012. [PMID: 37635325 DOI: 10.1093/intbio/zyad012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 07/10/2023] [Accepted: 08/08/2023] [Indexed: 08/29/2023]
Abstract
Neurodegenerative disorders (NDDs) are known to exhibit genetic overlap and shared pathophysiology. This study aims to find the shared genetic architecture of Alzheimer's disease (AD) and Parkinson's disease (PD), two major age-related progressive neurodegenerative disorders. The gene expression profiles of GSE67333 (containing samples from AD patients) and GSE114517 (containing samples from PD patients) were retrieved from the Gene Expression Omnibus (GEO) functional genomics database managed by the National Center for Biotechnology Information. The web application GREIN (GEO RNA-seq Experiments Interactive Navigator) was used to identify differentially expressed genes (DEGs). A total of 617 DEGs (239 upregulated and 379 downregulated) were identified from the GSE67333 dataset. Likewise, 723 DEGs (378 upregulated and 344 downregulated) were identified from the GSE114517 dataset. The protein-protein interaction networks of the DEGs were constructed, and the top 50 hub genes were identified from the network of the respective dataset. Of the four common hub genes between two datasets, C-X-C chemokine receptor type 4 (CXCR4) was selected due to its gene expression signature profile and the same direction of differential expression between the two datasets. Mavorixafor was chosen as the reference drug due to its known inhibitory activity against CXCR4 and its ability to cross the blood-brain barrier. Molecular docking and molecular dynamics simulation of 51 molecules having structural similarity with Mavorixafor was performed to find two novel molecules, ZINC49067615 and ZINC103242147. This preliminary study might help predict molecular targets and diagnostic markers for treating Alzheimer's and Parkinson's diseases. Insight Box Our research substantiates the therapeutic relevance of CXCR4 inhibitors for the treatment of Alzheimer's and Parkinson's diseases. We would like to disclose the following insights about this study. We found common signatures between Alzheimer's and Parkinson's diseases at transcriptional levels by analyzing mRNA sequencing data. These signatures were used to identify putative therapeutic agents for these diseases through computational analysis. Thus, we proposed two novel compounds, ZINC49067615 and ZINC103242147, that were stable, showed a strong affinity with CXCR4, and exhibited good pharmacokinetic properties. The interaction of these compounds with major residues of CXCR4 has also been described.
Collapse
Affiliation(s)
- Rahul Tripathi
- Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly Delhi College of Engineering), Delhi, India
| | - Pravir Kumar
- Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly Delhi College of Engineering), Delhi, India
| |
Collapse
|
2
|
Simmons SJ, Oliver CF, McCloskey NS, Reitz AB, Nayak SU, Watson MN, Rawls SM. Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonist. Drug Alcohol Depend 2022; 230:109204. [PMID: 34871976 PMCID: PMC8729820 DOI: 10.1016/j.drugalcdep.2021.109204] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/15/2021] [Accepted: 11/16/2021] [Indexed: 01/03/2023]
Abstract
Chemokine CXCR4 and CCR5 receptors are best known as HIV co-entry receptors, but evidence that CXCR4 or CCR5 blockade reduces rewarding and locomotor-stimulant effects of psychostimulants in rats suggests a role in psychostimulant use disorders. We investigated the impact of CXCR4 or CCR5 receptor antagonism on anxiety-related effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) in the elevated zero-maze (EZM) assay. Rats exposed to a 4-day MDPV binge dosing paradigm and tested 24 or 72 h post-treatment spent more time in the open compartment at the 24-h time point but less time at the 72-h post-binge time point. Daily administration of AMD 3100, a CXCR4 antagonist (10 mg/kg), or maraviroc, a CCR5 antagonist (2.5 mg/kg), during MDPV treatment inhibited the MDPV-induced increase in time spent in the open compartment. Neither antagonist affected the MDPV-induced reduction in time spent in the open compartment at the 72-h post-binge time point. Cocaine, administered in the same paradigm as MDPV, did not increase time spent in the open compartment 24-h post-binge, suggesting specificity to MDPV. The present results identify a surprising anxiolytic-like effect of MDPV 24 h after cessation of repeated exposure that is sensitive to chemokine CXCR4 and CCR5 receptor activity.
Collapse
Affiliation(s)
- Steven J. Simmons
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
| | - Chicora F. Oliver
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA
| | - Nicholas S. McCloskey
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
| | - Allen B. Reitz
- Fox Chase Chemical Diversity Center Inc., Doylestown, PA, USA
| | - Sunil U. Nayak
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
| | - Mia N. Watson
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
| | - Scott M. Rawls
- Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA,Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA
| |
Collapse
|
3
|
Smith MA, Ballard SL, Ballesteros CF, Bonge SA, Casimir AT, Childs LM, Feinstein MA, Griffith AK, Johansen AN, Lee D, Mauser AC, Moses CM, Robertson IJ, Robles JU, Strickland JC, Walters ME, Yoo SJ. Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor. Front Psychiatry 2021; 12:790471. [PMID: 35069292 PMCID: PMC8766790 DOI: 10.3389/fpsyt.2021.790471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Accepted: 12/08/2021] [Indexed: 11/16/2022] Open
Abstract
Opioids and stimulants are often used in combination for both recreational and non-recreational purposes. High-efficacy mu opioid agonists generally increase the behavioral effects of stimulants, whereas opioid receptor antagonists generally attenuate the behavioral effects of stimulants; however, less is known regarding the interactions between stimulants and opioids possessing low to intermediate efficacy at the mu receptor. The purpose of this study was to examine the role of an opioid's relative efficacy at the mu receptor in altering the behavioral effects of dextro(d-)amphetamine. To this end, opioids possessing a range of relative efficacy at the mu receptor were examined alone and in combination with cumulative doses of d-amphetamine on a test of open-field, locomotor activity in male rats. Levorphanol, buprenorphine, butorphanol, nalbuphine, (-)-pentazocine, (-)-metazocine, (-)-cyclazocine, (-)-NANM, and nalorphine increased the locomotor effects of d-amphetamine in either an additive or greater-than-additive manner according to an effect-additive model. Only the selective, high-efficacy kappa agonist, spiradoline, and the non-selective opioid receptor antagonist, naloxone, failed to increase the effects of d-amphetamine under the conditions examined. These data indicate that opioids possessing a large range of relative efficacy at the mu receptor, including those possessing very low relative efficacy, significantly increase the locomotor effects of d-amphetamine.
Collapse
Affiliation(s)
- Mark A Smith
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Shannon L Ballard
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Clarise F Ballesteros
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Samantha A Bonge
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Alexander T Casimir
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Lauren M Childs
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Max A Feinstein
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Annie K Griffith
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Alexandra N Johansen
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Daegeon Lee
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - A Caroline Mauser
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Cassidy M Moses
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Ian J Robertson
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Javier U Robles
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Justin C Strickland
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Mary E Walters
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| | - Seeley J Yoo
- Program in Neuroscience, Department of Psychology, Davidson College, Davidson, NC, United States
| |
Collapse
|